The ADNA (Advanced Diagnostics for New Therapeutic Approaches) program intends to contribute to the development of theranostics in the areas of infectious diseases, cancer and rare genetic diseases, providing healthcare professionals with innovative products and services for more personalized medicine.
Coordinated by Institut Mérieux, the ADNA program brings together :
- bioMérieux and GenoSafe in the field of diagnostics,
- Généthon and Transgene in the field of therapeutics.
Other partners contribute their expertise, including the French Atomic Energy Commission (CEA), the French National Scientific Research Center (CNRS), the Lyon University Hospitals (HCL), STMicroelectronics, and Claude Bernard University in Lyon (UCBL).